FBLG FibroBiologics, Inc. Insider Trading

Chief Scientific Officer Khoja Hamid bought 30,000 shares of FBLG at $0.38; prior two FBLG buys posted 90-day returns of +1355.5% and +3815.8%

Khoja Hamid purchased 30,000 shares at $0.38, doubling his FBLG holdings from 31,250 to 61,250 shares. His cross-ticker track record shows 2 prior buys with an average 90-day return of +2585.6% and a 100% 90-day win rate, while his two prior buys specifically at FBLG (May 2025 and August 2024) each showed substantial 90-day gains (+1355.5% and +3815.8% respectively), both well-timed. This purchase occurs as the stock trades at $8.38, down 69.6% from its 52-week high of $27.60, yet up 51.1% in the past 30 days and 58.9% over 90 days. The company remains unprofitable with net income of $-5.8M against a market cap of $566.4M, but notably 3 other insiders also bought within the past 14 days, forming a cluster buy pattern. The combination of a historically accurate insider's large relative purchase (+96% to holdings), strong 30/90-day price recovery, and multi-insider buying interest suggests elevated conviction in near-term recovery prospects.

CEO Pete O'Heeron bought 51,500 shares (3 purchases) at blended $0.38 avg amid +32.4% 30-day rebound and cluster buy activity.

O'Heeron executed 3 separate purchases totaling 51,500 shares for $19,530.86 across March 2–4, 2026, at transaction prices ranging from $0.35 to $0.41. This adds 0.9% to his holdings of 5.96M shares post-transaction. The timing coincides with sharp price recovery: the stock has climbed 32.4% over 30 days and 44.4% over 90 days from depressed levels, currently trading at $7.51, -72.8% below its 52-week high of $27.60. Notably, 3 other insiders also bought within the past 14 days, forming a cluster buy pattern. However, the company remains unprofitable (net income $-5.8M), and O'Heeron's own cross-ticker track record shows modest timing accuracy (33.33% 90-day win rate on 9 prior buys, though his single prior FBLG purchase in August 2024 yielded extraordinary 90-day returns of +3787.2%). The CEO's accumulation during a recovery period, without fundamental improvement, warrants investor attention to whether this reflects conviction in turnaround prospects or a routine portfolio adjustment.

CFO Davis Jason buys 70,000 shares at $0.41; company unprofitable ($-5.8M net income); cluster pattern with 2 other insiders buying within 14 days.

CFO Jason Davis purchased 70,000 shares at $0.41 on 2026-03-02, with this representing his initial holdings position in FibroBiologics. The transaction occurs at a significant discount to the 52-week high of $27.60, representing a -71.8% gap from peak levels. Most notably, this purchase is part of a cluster pattern: 2 other insiders also bought within the past 14 days, suggesting coordinated accumulation by the leadership team. However, the company's fundamentals remain challenged—it reported a net loss of $-5.8M over its most recent full fiscal year. While the stock has rebounded +52.6% over 90 days and +17.2% over 30 days, the cluster buying by multiple executives during unprofitable operations warrants investor scrutiny to understand whether leadership sees inflection potential or if other material developments are driving the acquisitions.

General Counsel Ruben Garcia buys 40,000 shares of FBLG at $0.33; stock at -69.6% from 52-week high; cluster buy pattern detected.

Ruben Garcia, General Counsel, purchased 40,000 shares at $0.33 on 2026-02-27, increasing his holdings by 28.6% to 180,000 shares total. The transaction occurred at a significant discount to the 52-week high of $27.60, though the stock has recovered 26.4% over the past 30 days and 59.4% over 90 days from depressed levels. Notably, 2 other insiders bought FBLG within the past 14 days, forming a cluster buy pattern that suggests coordinated or corroborating conviction at these price levels. The company reported negative net income of $-5.8M in its most recent fiscal year, so this buy occurs in a fundamentally unprofitable context where price momentum rather than earnings improvement appears to be driving the recent recovery.

General Counsel Ruben Garcia buys 140,000 shares of FBLG at $0.34 in initial purchase; stock trades -83.7% from 52-week high at $7.86

FBLG General Counsel Ruben Garcia purchased 140,000 shares at $0.34 per share for a total of $47,600.00, representing his first disclosed holdings in the company. The transaction occurs as FBLG trades at $7.86, down 83.7% from its 52-week high of $48.20, and the company reported a full-year net income of $-5,778,000.00, indicating ongoing unprofitability. The entry at a deeply depressed price relative to recent trading history and the executive's new full-position initiation merit investor attention to whether this reflects management confidence in a turnaround strategy or other motivations, particularly given the company's negative earnings backdrop.

Chief Scientific Officer Hamid buys 20,000 FBLG shares at $0.84, tripling position; stock down -93.7% from $259.20 52-week high.

Khoja Hamid, Chief Scientific Officer, purchased 20,000 shares at $0.84 on 2025-05-27, increasing his holdings from 11,250 to 31,250 shares (+177.8% net change). The transaction occurs while FBLG trades at $16.24, down -93.7% from its 52-week high of $259.20 and down -33.4% over the last 30 days. Critically, the company reported net income of $-5.0M over its most recent full fiscal year, establishing a backdrop of unprofitability. Hamid's prior buy at FBLG on 2024-08-12 generated a 90-day return of +3815.8%, suggesting his prior purchase timing proved well-timed at this ticker; however, that historical pattern does not extend to this current transaction, which has already declined over the trailing 30- and 90-day periods shown in the PRICE data.

CEO O'Heeron buys 8,500 shares of FBLG at $1.91 (Aug 12) amid -93.7% decline from 52-week high

CEO Pete O'Heeron purchased 8,500 shares at $1.91, bringing his total holdings to 6,056,647 shares. The buy occurred in a context of severe price deterioration: FBLG is down 93.7% from its 52-week high and has declined 61.4% over the preceding 30 days and 83.8% over 90 days. O'Heeron's cross-ticker track record shows 6 prior open-market buys with a 90-day average return of +136.7%, though the 33.33% win rate indicates significant variability in outcomes. The company reported a net loss for its most recent full fiscal year, though a recent quarter showed $898,000 in net income, creating mixed signals about profitability trajectory. This open-market purchase by the CEO deserves monitoring given the stock's sharp deterioration, but the modest share count increase (0.1% of pre-transaction holdings) and the insider's mixed historical returns limit the strength of any signal.

CSO Khoja Hamid bought 10,000 shares of FBLG at $1.90; stock now at $36.60, down 93.7% from 52-week high of $582.00.

Chief Scientific Officer Khoja Hamid purchased 10,000 shares at $1.90 on 2024-08-12, increasing his holdings from 1.2K to 11.2K shares. The transaction occurred after severe price deterioration: the stock has declined 93.7% from its 52-week high of $582.00 and fallen 83.8% over the past 90 days. While the company reported net income of $898.0K, this represents a recovery from being unprofitable over its most recent full fiscal year. The sharp downward momentum and historical loss-making status present context for evaluating whether this near-trivial-cost basis ($1.90) reflects an opportunity or risk; the 800% increase in his own holdings relative to his small pre-existing position of 1.2K shares marks the transaction as material to his personal exposure.